CLAIMS

What is claimed is:

1. Use of a composition comprising nanoparticles comprising a taxane and a carrier protein in the manufacture of a medicament for treating a ~~proliferative disease~~cancer in an individual, wherein the medicament is to be administered intravenously in combination with an effective amount of ~~an inhibitor of DNA methyltransferase administered orally~~ decitabine.

2. The use according to claim 1, wherein the medicament is to be administered with a platinum-based agent.

~~3. The use according to claim 1, wherein the other agent is azacitidine.~~

~~4. The use according to claim 1, wherein the other agent is decitabine.~~

~~5. The use according to any one of claims 1-4, wherein the proliferative disease is cancer.~~

3~~6~~. The use according to claim ~~5~~1, wherein the cancer is breast cancer.

4~~7~~. The use according to claim 3~~6~~, wherein the individual is negative for ER, PR, or HER2.

5~~8~~. The use according to claim 4~~7~~, wherein the individual is negative for ER, PR, and HER2.

69. The use according to claim 51, wherein the cancer is ovarian cancer.

710. The use according to claim 51, wherein the cancer is non-small lung cancer.

811. The use according to claim 51, wherein the cancer is endometrial cancer.

912. The use according to claim 51, wherein the cancer is cervical cancer.

1013. The use according to claim 51, wherein the cancer is pancreatic cancer.

1114. The use according to claim 51, wherein the cancer is melanoma.

1215. The use according to claim 51, wherein the cancer is bladder cancer.

1316. The use according to claim 51, wherein the cancer is head and neck cancer.

1417. The use according to any one of claims 1-1316, wherein the composition comprising nanoparticles comprising taxane and albumin and ~~the other agent~~decitabine are to be administered simultaneously.

1518. The use according to any one of claims 1-1316, wherein the composition comprising nanoparticles of taxane and albumin and ~~the other agent~~decitabine are to be administered sequentially.

1619. The use according to any one of claims 1-1316, wherein the composition comprising nanoparticles of taxane and albumin and ~~the other agent~~decitabine are to be administered concurrently.

1720. The use according to any one of claims 1-1619, wherein the taxane is paclitaxel.

1821. The use according to any one of claims 1-1720, wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm.

1922. The use according to any one of claims 1-1821, wherein the carrier protein is albumin.

2023. The use according to claim 1922, wherein the albumin is human serum albumin.

2124. The use according to claim 1922, wherein the albumin is human albumin.

2225. The use according to any of claims 22-2419-21, wherein the weight ratio of the albumin and the taxane in the nanoparticle composition is about 1:1 to about 18:1.

2326. The use according to any of claims 22-2519-22, wherein the weight ratio of the albumin and the taxane in the nanoparticle composition is about 1:1 to about 9:1.

2427. The use according to any one of claims 1-2326, wherein the individual is a human.

2528. The use according to any one of claims 1-2427, wherein the nanoparticles in the composition are to be administered intravenously.

2629. The use according to claim 2528, wherein the amount of taxane in the composition is between about 80 mg/m^2 to about 150 mg/m^2.

2730. The use according to claim 2629, wherein the amount of taxane in the composition is between about 100 mg/m^2 to about 125 mg/m^2.

2831. The use according to any one of claims 1-2730, wherein the ~~other agent~~ decitabine in the composition is to be administered orally.

2932. The use according to claim 2831, wherein the effective amount of the ~~other agent~~ decitabine in the composition is between about 80 mg to about 1000 mg.

3033. The use according to claim 2932, wherein the effective amount of the ~~other agent~~decitabine in the composition is between about 100 mg to about 200 mg.

3134. A kit comprising: a) a composition comprising nanoparticles comprising a taxane and a carrier protein, and b) an effective amount of at least one other agent ~~that inhibits DNA methyltransferase, wherein the inhibitor of DNA methyltransferase is suitable for oral administration~~ , wherein the other agent is decitabine.

~~35. The kit according to claim 34, wherein the other agent is azacitidine.~~

~~36. The kit according to claim 34, wherein the other agent is decitabine.~~

3237. The kit according to ~~any one of~~ claims ~~34-36~~31, wherein the taxane is paclitaxel.

3338. The kit according to any one of claims ~~34-37~~31-32, wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm.

3439. The kit according to any one of claims ~~34-38~~31-33, wherein the carrier protein is albumin.

3540. The kit according to claim 3439, wherein the albumin is human serum albumin.

3641. The kit according to claim 3439, wherein the albumin is human albumin.

3742. A medicine comprising: a) a composition comprising nanoparticles comprising a taxane and a carrier protein, and b) an effective amount of at least one other agent ~~that inhibits DNA methyltransferase, wherein the inhibitor of DNA methyltransferase is suitable for oral administration~~ , wherein the other agent is decitabine.

~~43. The medicine according to claim 42, wherein the other agent is azacitidine.~~

~~44. The medicine according to claim 42, wherein the other agent is decitabine.~~

38~~45~~. The medicine according to ~~any one of~~ claims ~~42-44~~37, wherein the taxane is paclitaxel.

39~~46~~. The medicine according to any one of claims ~~42-45~~37-38, wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm.

40~~47~~. The medicine according to any one of claims ~~42-46~~37-39, wherein the carrier protein is albumin.

41~~48~~. The medicine according to claim ~~47~~40, wherein the albumin is human serum albumin.

42~~49~~. The medicine according to claim ~~47~~40, wherein the albumin is human albumin.